Novartis charged much more in the U.S. for some drugs than in other countries

The difference in pricing ranged anywhere from 45 percent to 176 percent, after adjusting for currency fluctuations and packaging.

An axiom in the overheated debate about prescription drug pricing is that Americans are often charged more than what is paid by people in other countries. And internal data from one large drug maker illustrates the point.

In 2014, the most recent year for which data was available, Novartis () headquarters in Switzerland charged its U.S. subsidiary significantly more for four medicines than what its subsidiaries paid in roughly a dozen other countries. These included several well-to-do nations

You're reading a preview, sign up to read more.

More from STAT

STAT6 min read
Opinion: The Indian Pharmaceutical Industry Is In Denial Over Drug-quality Charges
If Americans are expecting India to improve the quality of the medicines it makes, they will be waiting a long time for that to happen.
STAT4 min readSociety
Opinion: More State Spending On Health Care May Be Eroding Americans’ Health
In many states, investing in communities lags, squeezed aside by increased spending on health care. That sets up a vicious cycle leading to increased rates of premature deaths and costly…
STAT4 min readPolitics
Opinion: Economic Barriers To Organ Transplants From Living Donors Must Be Removed
Many people would willingly donate a kidney or part of the liver but can't afford to. It's time to reduce barriers — including economic ones — so anyone who wants…